XML 36 R58.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Collaborations - Additional Information (Detail) - USD ($) | 1 Months Ended | 12 Months Ended |
--- | --- | --- | ---
Jan. 31, 2020 | Dec. 31, 2018 | Feb. 28, 2018 | Dec. 31, 2019 | Dec. 08, 2016
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |
Deferred revenue |  |  |  | $ 15,000,000 |
Pfizer Inc | Collaboration Agreement |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |
Milestone payment |  |  | $ 1,000,000 | $ 0 |
Pfizer Inc | Collaboration Agreement | Maximum |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |
Contingent cash payments upon achievement of clinical, regulatory and commercial milestones |  |  |  |  | $ 17,500,000
ISU Abxis | Amended and Restated License Agreement |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |
Regulatory and development milestone payment |  | $ 2,500,000 |  |  |
ISU Abxis | Amended and Restated License Agreement | Maximum |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |
Milestone payment |  | 19,500,000 |  |  |
Commercial milestone payments |  | $ 17,000,000 |  |  |
Biogen | Exclusive License |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |
Research services |  |  |  | 30 months |
Research services option to extend |  |  |  | 12 months |
Deferred revenue |  |  |  | $ 15,000,000 |
Biogen | Exclusive License | Subsequent Event |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |
Up-front payments received | $ 15,000,000 |  |  |  |
Development milestones payment receivable | 340,000,000 |  |  |  |
Sales milestones receivable. | $ 340,000,000 |  |  |  |

X
- Definition Commercial milestone payments. + References No definition available. + Details
Name: | cbio_CommercialMilestonePayments
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Development milestones payment Receivable. + References No definition available. + Details
Name: | cbio_DevelopmentMilestonesPaymentReceivable
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone contingent cash payments obligation. + References No definition available. + Details
Name: | cbio_MilestoneContingentCashPaymentsObligation
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone payments. + References No definition available. + Details
Name: | cbio_MilestonePayments
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Regulatory and development milestone payment. + References No definition available. + Details
Name: | cbio_RegulatoryAndDevelopmentMilestonePayment
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research services agreement option to extend. + References No definition available. + Details
Name: | cbio_ResearchServicesAgreementOptionToExtend
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research services. + References No definition available. + Details
Name: | cbio_ResearchServicesAgreementTerm
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sales milestones receivable. + References No definition available. + Details
Name: | cbio_SalesMilestoneReceivable
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash received from licensees for license fees during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=cbio_PfizerIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cbio_IsuAbxisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=cbio_AmendedAndRestatedLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cbio_BiogenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=cbio_ExclusiveLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |